SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (8189)8/27/2000 11:52:29 PM
From: Vector1  Read Replies (1) | Respond to of 9719
 
David,
MLNM is much more than their obesity program which is actually a small part. Quite simply MLNM is the envy of the industry in terms of their parnerships and the quaiity of the work they produce. IMO they are the most likely of the genomic companies the bridge the gap and become a pharma. They are expensive, but so was CSCO 7 years ago. This company is a winnner.
V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News